LONDON (Thomson Financial) - Allergy Therapeutics PLC said it has entered into a 40 mln eur debt facility with the Royal Bank of Scotland to finance the final stages of the development of its ultra-short course vaccines to treat hayfever.
LONDON (Thomson Financial) - Allergy Therapeutics PLC said it has entered into a 40 mln eur debt facility with the Royal Bank of Scotland to finance the final stages of the development of its ultra-short course vaccines to treat hayfever.
